Why the latest earnings and share filing matter for Ocular Therapeutix (OCUL)

Ocular Therapeutix (OCUL) just released fourth quarter and full year 2025 results alongside a new shelf registration. Together, these updates put profitability trends and potential share dilution in clear focus for investors.

For the fourth quarter, Ocular Therapeutix reported revenue of US$13.25 million compared with US$17.08 million a year earlier. The company posted a net loss of US$64.65 million versus US$48.39 million in the prior year quarter, while basic and diluted loss per share from continuing operations held at US$0.29.

For the full year 2025, revenue came in at US$51.95 million compared with US$63.72 million in the previous year. Net loss for the year was US$265.94 million compared with US$193.51 million a year earlier, with basic and diluted loss per share from continuing operations of US$1.42 versus US$1.22.

On the same date, the company also filed a shelf registration covering up to US$8.29 million of common stock, representing 974,000 shares in an ESOP related offering. While this is a relatively small potential issuance in dollar terms, it still introduces the possibility of dilution that existing shareholders may want to factor into their assessment.

Taken together, the latest update highlights two key questions for anyone tracking the stock: how Ocular Therapeutix manages its path toward lower losses over time, and how any future share issuance tied to this filing could affect an investor’s ownership stake.

At a share price of US$8.88, Ocular Therapeutix has seen pressure in recent weeks, with a 1 day share price return of 1.99% decline and a 30 day share price return of 19.78% decline. However, its 1 year total shareholder return of 21.98% and 3 year total shareholder return of 41.63% show that longer term holders have still seen gains. This suggests that recent earnings and the shelf registration may be prompting investors to reassess both growth potential and risk.

If this update has you reassessing risk and opportunity in biotech, it could be a good time to look at 25 healthcare AI stocks as another way to find specialised healthcare names with AI exposure.

So with the share price under pressure yet trading at a large discount to analyst targets and some intrinsic value indicators, is Ocular Therapeutix offering mispriced potential here, or is the market already factoring in future growth?

Most Popular Narrative: 63.3% Undervalued

At a last close of US$8.88 versus a narrative fair value of about US$24.17, Ocular Therapeutix is framed as heavily mispriced, with that gap tied directly to expectations around its retinal pipeline.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see what sits behind that confidence in AXPAXLI? The narrative leans on aggressive revenue ramps, fatter margins, and a future earnings multiple more often associated with higher profile sectors.

Result: Fair Value of $24.17 (UNDERVALUED)

However, this hinges on AXPAXLI clearing key clinical and regulatory hurdles. Any delay or disappointment here could quickly challenge the current undervalued narrative.

Another Angle On Value

The AI narrative leans heavily on future growth to argue Ocular Therapeutix is undervalued, but the SWS DCF model goes even further, with a fair value estimate of about $86.45 per share versus the current $8.88. That is a very large gap. Which number do you trust more with your own money?

Build Your Own Ocular Therapeutix Narrative

If you see the numbers differently or prefer to test your own assumptions, you can pull the data together, build your thesis, and Do it your way in just a few minutes.

A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are weighing what to do next after looking at Ocular Therapeutix, this is a smart moment to widen your watchlist using focused stock ideas.

• Target potential value opportunities by checking out our hand picked list of 53 high quality undervalued stocks that pair quality fundamentals with discounted prices.
• Strengthen the core of your portfolio by reviewing companies in the solid balance sheet and fundamentals stocks screener (44 results) that put financial resilience front and center.
• Get ahead of the crowd by scanning our screener containing 23 high quality undiscovered gems and see which under the radar names fit your style before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.